In vivo Magnetic Resonance Imaging of Atherosclerotic Lesions with a Newly Developed Evans Blue-DTPA-Gadolinium Contrast Medium in Apolipoprotein-E-Deficient Mice

2007 ◽  
Vol 45 (2) ◽  
pp. 123-128 ◽  
Author(s):  
Satoshi Yasuda ◽  
Kenjiro Ikuta ◽  
Toyokazu Uwatoku ◽  
Keiji Oi ◽  
Kohtaro Abe ◽  
...  
2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Fei Yan ◽  
Wei Yang ◽  
Xiang Li ◽  
Hongmei Liu ◽  
Xiang Nan ◽  
...  

The goal of this study is to investigate the feasibility of using CD81- (Cluster of Differentiation 81 protein-) targeted microparticles of iron oxide (CD81-MPIO) for magnetic resonance imaging (MRI) of the murine atherosclerosis. CD81-MPIO and IgG- (Immunoglobulin G-) MPIO were prepared by covalently conjugating, respectively, with anti-CD81 monoclonal and IgG antibodies to the surface of the tosyl activated MPIO. The relevant binding capability of the MPIO was examined by incubating them with murine bEnd.3 cells stimulated with phenazine methosulfate (PMS) and its effect in shortening T2 relaxation time was also examined. MRI in apolipoprotein E-deficient mice was studied in vivo. Our results show that CD81-MPIO, but not IgG-MPIO, can bind to the PMS-stimulated bEnd.3 cells. The T2 relaxation time was significantly shortened for stimulated bEnd.3 cells when compared with IgG-MPIO. In vivo MRI in apolipoprotein E-deficient mice showed highly conspicuous areas of low signal after CD81-MPIO injection. Quantitative analysis of the area of CD81-MPIO contrast effects showed 8.96- and 6.98-fold increase in comparison with IgG-MPIO or plain MPIO, respectively (P<0.01). Histological assay confirmed the expression of CD81 and CD81-MPIO binding onto atherosclerotic lesions. In conclusion, CD81-MPIO allows molecular assessment of murine atherosclerotic lesions by magnetic resonance imaging.


2004 ◽  
Vol 39 (10) ◽  
pp. 585-590 ◽  
Author(s):  
Eug??ne P. McFadden ◽  
Linda Chaabane ◽  
Francis Contard ◽  
Daniel Guerrier ◽  
Andr?? Briguet ◽  
...  

2011 ◽  
Vol 78 (3) ◽  
pp. 136-137 ◽  
Author(s):  
Mika Murabayashi ◽  
Taku Sugita ◽  
Keiko Hirakawa ◽  
Hideto Kuribayashi ◽  
Ikuo Mori ◽  
...  

Blood ◽  
2005 ◽  
Vol 105 (1) ◽  
pp. 420-425 ◽  
Author(s):  
Stasia A. Anderson ◽  
John Glod ◽  
Ali S. Arbab ◽  
Martha Noel ◽  
Parwana Ashari ◽  
...  

Abstract Bone marrow-derived endothelial precursor cells incorporate into neovasculature and have been successfully used as vehicles for gene delivery to brain tumors. To determine whether systemically administered Sca1+ bone marrow cells labeled with superparamagnetic iron oxide nanoparticles can be detected by in vivo magnetic resonance imaging in a mouse brain tumor model, mouse Sca1+ cells were labeled in vitro with ferumoxides-poly-l-lysine complexes. Labeled or control cells were administered intravenously to glioma-bearing severe combined immunodeficient (SCID) mice. Magnetic resonance imaging (MRI) was performed during tumor growth. Mice that received labeled cells demonstrated hypointense regions within the tumor that evolved over time and developed a continuous dark hypointense ring at a consistent time point. This effect was not cleared by administration of a gadolinium contrast agent. Histology showed iron-labeled cells around the tumor rim in labeled mice, which expressed CD31 and von Willebrand factor, indicating the transplanted cells detected in the tumor have differentiated into endothelial-like cells. These results demonstrate that MRI can detect the incorporation of magnetically labeled bone marrow-derived precursor cells into tumor vasculature as part of ongoing angiogenesis and neovascularization. This technique can be used to directly identify neovasculature in vivo and to facilitate gene therapy by noninvasively monitoring these cells as gene delivery vectors. (Blood. 2005;105:420-425)


Sign in / Sign up

Export Citation Format

Share Document